Summary
This randomised, double‐blinded, controlled trial was designed to identify the optimal dose of remifentanil for cough suppression without adverse effects during emergence from sevoflurane‐remifentanil anaesthesia for thyroidectomy. One hundred and four patients were randomly assigned to maintain target effect‐site concentrations of remifentanil at 0 (control group), 1.0 (remifentail 1 group), or 1.5 ng.ml−1 (remifentanil 1.5 group) during emergence. The incidence of coughing was lower in the remifentanil 1.5 group (31%) than in the control group (74%) or remifentanil 1 group (63%) (p = 0.0004). In addition, the severity of coughing during extubation was lower in the remifentanil 1.5 group (median (IQR [range]) 0 (0–1 [0–1]) than in the control group (1 (0–2 [0–3])) and remifentanil 1 group (1 (0–2 [0–3])) (p = 0.004). Haemodynamic changes were reduced, but emergence time and stay in the post‐anaesthesia care unit was prolonged in the remifentanil 1.5 group. Maintaining the remifentanil effect‐site concentration at 1.5 ng.ml−1 during emergence from sevoflurane‐remifentanil anaesthesia reduces the incidence and severity of coughing without serious adverse events and may provide haemodynamic stability in patients undergoing thyroidectomy. However, awakening may be delayed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.